From the blog

A Clinical Study of Anetumab Ravtansine in Adults With Solid Tumors Who Have Been Treated in Previous Bayer-sponsored Anetumab Ravtansine Studies

Published: September 20, 2019

Primary Outcome Measures

  1. Incidence of treatment-emergent adverse events (TEAEs) [ Time Frame: Up to 5.5 years ]
  2. Incidence of treatment-emergent serious adverse events (TESAEs) [ Time Frame: Up to 5.5 years ]
  3. Incidence of drug-related TEAEs [ Time Frame: Up to 5.5 years ]
  4. Incidence of drug-related TESAEs [ Time Frame: Up to 5.5 years ]

Secondary Outcome Measures

  1. Overall survival [ Time Frame: Up to 5.5 years ]

Inclusion Criteria

  • Participants ongoing in an applicable Bayer-sponsored anetumab ravtansine parent study at the time of its planned study closure.
  • For on-treatment participants: participant is eligible to receive the next dose of study intervention per the parent study protocol.

Exclusion Criteria

  • For on-treatment participants: a positive serum pregnancy test.
  • For on-treatment participants: use of one or more of the prohibited medications listed in the respective parent study protocol.
  • Participants who are receiving standard-of-care agent(s) but not anetumab ravtansine in the parent study, and are able to receive standard-of-care agent outside of the clinical study.
Contact Us
Have you received a diagnosis? *